Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Author Correction: Methods for randomized, blinded, controlled evaluation of putative disease interventions in multilaboratory, preclinical assessment networks.

Lab animal·2026
Same author

Methods for randomized, blinded, controlled evaluation of putative disease interventions in multilaboratory, preclinical assessment networks.

Lab animal·2026
Same author

A Bayesian design for dual-agent dose optimization with targeted therapies.

Journal of biopharmaceutical statistics·2025
Same author

Clinician and Patient Perspectives on a Patient-Facing Online Breast Cancer Symptom Visualization Tool.

JCO clinical cancer informatics·2025
Same author

PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Development of a Web-Based Interactive Tool for Visualizing Breast Cancer Clinical Trial Tolerability Data.

JCO clinical cancer informatics·2024

相关实验视频

Updated: Jun 14, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

在以常规毒性等级为指导的瘤学试验中发现剂量,使用连续剂量水平.

Mourad Tighiouart1, André Rogatko2

  • 1Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA 90069, USA.

Entropy (Basel, Switzerland)
|August 29, 2024
PubMed
概括

这项研究引入了一种新的贝叶斯适应设计,用于瘤学剂量检测试验. 这种新方法通过结合中间毒性数据来提高患者的安全性,从而使剂量升级更加谨慎,并有效地估计最大耐受剂量.

科学领域:

  • 在瘤学瘤学.
  • 临床试验设计 临床试验设计
  • 生物统计学 生物统计学

背景情况:

  • 传统的剂量确定试验通常仅依赖于二元剂量限制毒性 (DLT) 数据.
  • 这种二元方法可能无法完全捕捉不良事件的范围,可能会影响药物开发早期阶段的患者安全.

研究的目的:

  • 提出一种新的贝叶斯适应设计,用于早期瘤学试验中的剂量发现.
  • 通过将中等毒性等级 (等级2) 与DLT一起,提高患者的安全性.
  • 提高估计最大耐受剂量 (MTD) 的效率.

主要方法:

  • 该设计采用了过量控制原则的升级.
  • 它使用比例概率模型来描述剂量-毒性关系.
  • 中级2级毒性数据被整合为指导剂量调整,确保更谨慎的升级.

主要成果:

  • 贝叶斯适应性设计在估计MTD时证明了安全性和可接受的效率.
  • 在各种场景下,对真实MTD和2级毒性率进行了运行特征的评估.
  • 模拟证实了设计对20名患者的计划样本大小的稳定性.

结论:

关键词:
癌症第一阶段试验.连续剂量的连续剂量.最大的耐受剂量.顺序性毒性等级的毒性等级.过量控制 过量控制相对比率模型的比例赔率模型

更多相关视频

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K

相关实验视频

Last Updated: Jun 14, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K
  • 拟议的贝叶斯适应设计为瘤学中剂量升级提供了更安全,更精细的方法.
  • 整合中间毒性数据可以改善第一次在人体试验中的伦理考虑.
  • 该设计提供了高效的MTD估计,这对于推进新型癌症疗法至关重要.